Herniorrhaphy
Scientists at Creighton University publish research in herniorrhaphy
Published in Biotech Business Week, January 5th, 2009
" We present a randomized controlled trial to evaluate the value of the cyclo-oxygenase-2 (COX-2) inhibitor, rofecoxib, as an adjuvant for pain management for patients undergoing a conventional Lichtenstein inguinal herniorrhaphy. The drug was removed from the market coincidentally with the conclusion of the trial due to thrombotic complications," scientists writing in the journal Hernia report.
"We believe that the data remains important, however, because of the imminent release of similar compounds with a better safety profile. No industry support was sought or accepted for this trial, with the exception of the study drug and an identical placebo preparation...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Instituto Gulbenkian de Ciencia
First experimental evidence for speedy adaptation to pesticides by worm species - JAMA and Archives Journals
Among older adults, prescription and over-the-counter medications are commonly used together - MedInsight Research Institute
New study shows that a cough medicine ingredient could effectively treat prostate cancer - NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Hepatitis C treatment reduces the virus but liver damage continues - Research
Blind man walking: With no visual awareness, man navigates obstacle course flawlessly - Saint Louis University
Using math to understand hep. C: Patterns paint picture of who will respond to treatment - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
